OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NCEL$3.1859

National Bank of Pakistan

Biotechnology & Medical ResearchVerified

The company's capital structure is characterized by a strong liquidity position, with cash and equivalents amounting to PKR 1,665,400,000, which is significantly higher than its total liabilities of PKR 826,760,000. The current ratio of 2.69 indicates a robust short-term liquidity position. However, the company has no long-term debt, and the debt-to-equity ratio is 0.0, suggesting a conservative capital structure. Profitability metrics are concerning, with a negative return on equity (ROE) of -1.4085 and a negative return on assets (ROA) of -0.887. These figures are well below the industry median for ROE and ROA, which typically range between 10% and 15% for firms in the Biotechnology & Medical Research industry. The company's net income is negative at PKR -1,980,810,000, and its operating income is also negative at PKR -1,880,140,000, indicating operational inefficiencies. The company's revenue is not disclosed in the provided data, but the absence of revenue data and the negative net income suggest a lack of transparency or operational challenges. The company's market share and competitor exposure are not quantified in the available data, but the absence of revenue data implies a potential concentration risk in its business model. The company's growth trajectory is negative, with no clear indication of improvement in the current fiscal year. The outlook for the next fiscal year is also uncertain, as the company has not provided specific revenue growth projections. The negative operating cash flow of PKR -4,267,880,000 and the negative free cash flow of PKR -4,057,590,000 suggest that the company is not generating sufficient cash to sustain operations or fund growth. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative net income and operating income suggest a high operational risk. The dilution potential is low, and no adjustments have been applied to the valuation metrics. Recent events and filings do not provide specific details on the company's operational challenges or strategic initiatives. The absence of revenue data and the negative financial performance suggest that the company may be facing significant operational and financial challenges. The ESG scores indicate moderate governance and social performance, but the ESG controversies score of 100.00 suggests that the company has not been involved in any major controversies.

30-day price · NCEL+0.65 (+25.9%)
Low$2.49High$5.12Close$3.16As of22 May, 00:00 UTC
Profile
CompanyNational Bank of Pakistan
TickerNCEL.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. National Bank of Pakistan provides banking and financial services, including corporate and retail banking, investment services, and digital banking solutions.

Classification. The company is classified under the Healthcare sector, specifically in the Biotechnology & Medical Research industry, with a high confidence level of 0.92.

The company's capital structure is characterized by a strong liquidity position, with cash and equivalents amounting to PKR 1,665,400,000, which is significantly higher than its total liabilities of PKR 826,760,000. The current ratio of 2.69 indicates a robust short-term liquidity position. However, the company has no long-term debt, and the debt-to-equity ratio is 0.0, suggesting a conservative capital structure. Profitability metrics are concerning, with a negative return on equity (ROE) of -1.4085 and a negative return on assets (ROA) of -0.887. These figures are well below the industry median for ROE and ROA, which typically range between 10% and 15% for firms in the Biotechnology & Medical Research industry. The company's net income is negative at PKR -1,980,810,000, and its operating income is also negative at PKR -1,880,140,000, indicating operational inefficiencies. The company's revenue is not disclosed in the provided data, but the absence of revenue data and the negative net income suggest a lack of transparency or operational challenges. The company's market share and competitor exposure are not quantified in the available data, but the absence of revenue data implies a potential concentration risk in its business model. The company's growth trajectory is negative, with no clear indication of improvement in the current fiscal year. The outlook for the next fiscal year is also uncertain, as the company has not provided specific revenue growth projections. The negative operating cash flow of PKR -4,267,880,000 and the negative free cash flow of PKR -4,057,590,000 suggest that the company is not generating sufficient cash to sustain operations or fund growth. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative net income and operating income suggest a high operational risk. The dilution potential is low, and no adjustments have been applied to the valuation metrics. Recent events and filings do not provide specific details on the company's operational challenges or strategic initiatives. The absence of revenue data and the negative financial performance suggest that the company may be facing significant operational and financial challenges. The ESG scores indicate moderate governance and social performance, but the ESG controversies score of 100.00 suggests that the company has not been involved in any major controversies.
Key takeaways
  • The company has a strong liquidity position with a current ratio of 2.69 and no long-term debt.
  • Profitability metrics are negative, with a return on equity of -1.4085 and a return on assets of -0.887.
  • The company's revenue is not disclosed, and the negative net income suggests operational inefficiencies.
  • The company's growth trajectory is negative, with no clear indication of improvement in the current or next fiscal year.
  • The risk assessment indicates low liquidity and dilution risks, but the company's negative financial performance suggests a high operational risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyPKR
Revenue
Gross profit
Operating income-$1.9M
Net income-$2.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$4.3M
CapEx-$3.9k
Free cash flow-$4.1M
Total assets$2.2M
Total liabilities$826.8k
Total equity$1.4M
Cash & equivalents$1.7M
Long-term debt$0.00
Valuation
Market price$3.18
Market cap$17.0M
Enterprise value$15.3M
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B12.1
P/Tangible book12.1
Tangible book$1.4M
Net cash$1.7M
Current ratio2.7
Debt/Equity0.0
ROA-88.7%
ROE-1.4%
Cash conversion2.1%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricNCELActivity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity0.0%1.2% medp25 0.0% · p75 17.4%bottom quartile
Observations
IR observations
Last actual EPS-26.29 USD
Last actual revenue0.00 USD
Social pillar26.84 (0-100)
Governance pillar37.06 (0-100)
ESG controversies score100.00 (0-100, higher = fewer controversies)
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-22 17:20 UTC#fe915c1f
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 17:17 UTCJob: 8fbe85cd